Barclays PLC Purchases 12,152 Shares of Nature’s Sunshine Products, Inc. (NASDAQ:NATR)

Barclays PLC grew its position in shares of Nature’s Sunshine Products, Inc. (NASDAQ:NATR) by 51.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,602 shares of the company’s stock after acquiring an additional 12,152 shares during the period. Barclays PLC owned about 0.19% of Nature’s Sunshine Products worth $485,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Jacobs Levy Equity Management Inc. raised its position in Nature’s Sunshine Products by 7.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 67,258 shares of the company’s stock valued at $916,000 after purchasing an additional 4,820 shares during the last quarter. Wasatch Advisors LP raised its holdings in shares of Nature’s Sunshine Products by 23.2% during the third quarter. Wasatch Advisors LP now owns 696,184 shares of the company’s stock valued at $9,482,000 after acquiring an additional 131,174 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its stake in Nature’s Sunshine Products by 26.8% in the second quarter. Paradigm Capital Management Inc. NY now owns 695,079 shares of the company’s stock worth $10,475,000 after acquiring an additional 146,879 shares during the period. XTX Topco Ltd bought a new stake in Nature’s Sunshine Products in the second quarter valued at $180,000. Finally, Renaissance Technologies LLC increased its position in Nature’s Sunshine Products by 1.9% during the 2nd quarter. Renaissance Technologies LLC now owns 559,797 shares of the company’s stock valued at $8,436,000 after purchasing an additional 10,700 shares during the period. 79.40% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NATR has been the subject of several research analyst reports. StockNews.com raised shares of Nature’s Sunshine Products from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 10th. Canaccord Genuity Group started coverage on Nature’s Sunshine Products in a research report on Friday, September 13th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Canaccord Genuity Group started coverage on Nature’s Sunshine Products in a research note on Friday, September 13th. They issued a “buy” rating and a $18.00 target price for the company.

Insider Transactions at Nature’s Sunshine Products

In other news, major shareholder Fosun Pharmaceutical Shanghai sold 3,000 shares of Nature’s Sunshine Products stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $13.39, for a total value of $40,170.00. Following the completion of the transaction, the insider now owns 69,347 shares of the company’s stock, valued at $928,556.33. The trade was a 4.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 6,100 shares of company stock valued at $80,860 in the last ninety days. 4.70% of the stock is currently owned by corporate insiders.

Nature’s Sunshine Products Stock Performance

Shares of NATR opened at $14.56 on Friday. Nature’s Sunshine Products, Inc. has a fifty-two week low of $10.81 and a fifty-two week high of $21.72. The firm’s 50-day simple moving average is $15.23 and its two-hundred day simple moving average is $14.54. The stock has a market cap of $269.01 million, a PE ratio of 16.55 and a beta of 0.93.

Nature’s Sunshine Products Profile

Nature’s Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.